hamhurricane
Bluelighter
I think a previous vendor set a good example with their handling of the distribution of O-desmethyltramadol. It comes down to two things - price and and ease of access. If the quantities stay small and the availability is inconsistent then it is much more difficult for it to blossom into an meph-style craze. Also I think everyone is jumping the gun on this, are we really so certain it will have the same abuse potential as meth? So many simple substituted amphetamines have been available I don't see why this one would be any more problematic than, say, methylone.

